Adoptive cellular therapy for the treatment of cancer

General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology

Volumn , Issue , 2008, Pages 343-361

  Yee, Cassian ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919683762     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-6087-8_15     Document Type: Chapter

References (105)

1. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277-286.
2. Sakai, K., A. E. Chang, and S. Y. Shu. 1990. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma. Cancer Res 50:4371-4376.
3. Greenberg, P. D. 1986. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. Journal of Immunology 136:1917-1922.
4. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693-702.
5. Surman, D. R., M. E. Dudley, W. W. Overwijk, and N. P. Restifo. 2000. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 164:562-565.
6. Greenberg, P. D., D. E. Kern, and M. A. Cheever. 1985. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells. Journal of Experimental Medicine 161:1122-1134.
7. Frey, A. B., and S. Cestari. 1997. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Cell Immunol 178:79-90.
8. Cameron, R. B., P. J. Spiess, and S. A. Rosenberg. 1990. Synergistic antitumor activity of tumorinfiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 171:249-263.
9. Cheever, M. A., J. A. Thompson, D. E. Kern, and P. D. Greenberg. 1985. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. Journal of Immunology 134:3895-3900.
10. Cheever, M. A., P. D. Greenberg, A. Fefer, and S. Gillis. 1982. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968-980.
11. Zeh, H. J., D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. Journal of Immunology 162:989-994.
12. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 93:4102-4107.
13. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355.
14. Awwad, M., and R. J. North. 1989. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49:1649-1654.
15. North, R. J., and M. Awwad. 1987. T cell suppression as an obstacle to immunologically-mediated tumor regression: elimination of suppression results in regression. Prog Clin Biol Res 244:345-358.
16. Townsend, S. E., and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells [see comments]. Science 259:368-370.
17. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America 90:3539-3543.
18. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, D. M. Heimann, C. A. Klebanoff, Z. Yu, L. N. Hwang, L. Feigenbaum, A. M. Kruisbeek, S. A. Rosenberg, and N. P. Restifo. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569-580.
19. Weiden, P. L., K. M. Sullivan, N. Flournoy, R. Storb, and E. D. Thomas. 1981. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529-1533.
20. Porter, D. L., M. S. Roth, C. McGarigle, J. L. Ferrara, and J. H. Antin. 1994. Induction of graftversus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100-106.
21. Kolb, H. J., J. Mittermuller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465.
22. Dazzi, F., R. M. Szydlo, N. C. Cross, C. Craddock, J. Kaeda, E. Kanfer, K. Cwynarski, E. Olavarria, A. Yong, J. F. Apperley, and J. M. Goldman. 2000. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96:2712-2716.
23. Soiffer, R. J., E. P. Alyea, E. Hochberg, C. Wu, C. Canning, B. Parikh, D. Zahrieh, I. Webb, J. Antin, and J. Ritz. 2002. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 8:625-632.
24. Bonini, C., G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzoni, S. Rossini, F. Mavilio, C. Traversari, and C. Bordignon. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science 276:1719-1724.
25. Kolb, H. J., A. Schattenberg, J. M. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, F. van Rhee, J. Mittermueller, T. de Witte, E. Holler, and H. Ansari. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050.
26. Porter, D. L., B. L. Levine, N. Bunin, E. A. Stadtmauer, S. M. Luger, S. Goldstein, A. Loren, J. Phillips, S. Nasta, A. Perl, S. Schuster, D. Tsai, A. Sohal, E. Veloso, S. Emerson, and C. H. June. 2006. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107:1325-1331.
27. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 [see comments]. Journal of the National Cancer Institute 86:1159-1166.
28. Chang, A. E., A. Aruga, M. J. Cameron, V. K. Sondak, D. P. Normolle, B. A. Fox, and S. Shu. 1997. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Journal of Clinical Oncology 15:796-807.
29. Riddell, S. R., and P. D. Greenberg. 1990. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. Journal of Immunological Methods 128:189-201.
30. Yee, C., J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis, and P. D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168-16173.
31. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
32. Heslop, H. E., M. K. Brenner, and C. M. Rooney. 1994. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331:679-680.
33. Rooney, C. M., C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555.
34. Savoldo, B., J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y. F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, S. Gottschalk, M. J. Finegold, M. K. Brenner, C. M. Rooney, and H. E. Heslop. 2006. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). Blood
35. Gustafsson, A., V. Levitsky, J. Z. Zou, T. Frisan, T. Dalianis, P. Ljungman, O. Ringden, J. Winiarski, I. Ernberg, and M. G. Masucci. 2000. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807-814.
36. Straathof, K. C., C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, C. M. Rooney, and H. E. Heslop. 2005. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898-1904.
37. Bollard, C. M., L. Aguilar, K. C. Straathof, B. Gahn, M. H. Huls, A. Rousseau, J. Sixbey, M. V. Gresik, G. Carrum, M. Hudson, D. Dilloo, A. Gee, M. K. Brenner, C. M. Rooney, and H. E. Heslop. 2004. Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease. J Exp Med 200:1623-1633.
38. Bollard, C. M., C. Rossig, M. J. Calonge, M. H. Huls, H. J. Wagner, J. Massague, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2002. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99:3179-3187.
39. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
40. Sahin, U., O. Tureci, and M. Pfreundschuh. 1997. Serological identification of human tumor antigens. Current Opinion in Immunology 9:709-716.
41. Scanlan, M. J., A. O. Gure, A. A. Jungbluth, L. J. Old, and Y. T. Chen. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32.
42. Hermeking, H. 2003. Serial analysis of gene expression and cancer. Curr Opin Oncol 15:44-49.
43. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanomaspecific human cytotoxic T cell lines. Science 264:716-719.
44. Henderson, R. A., A. L. Cox, K. Sakaguchi, E. Appella, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 1993. Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. Proc Natl Acad Sci U S A 90:10275-10279.
45. Hunt, D. F., R. A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. L. Cox, E. Appella, and V. H. Engelhard. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261-1263.
46. Van Voorhis, W. C., L. S. Hair, R. M. Steinman, and G. Kaplan. 1982. Human dendritic cells. Enrichment and characterization from peripheral blood. J Exp Med 155:1172-1187.
47. Steinman, R. M., and M. D. Witmer. 1978. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 75:5132-5136.
48. Schultze, J. L., S. Michalak, M. J. Seamon, G. Dranoff, K. Jung, J. Daley, J. C. Delgado, J. G. Gribben, and L. M. Nadler. 1997. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100:2757-2765.
49. Groh, V., Y. Q. Li, D. Cioca, N. N. Hunder, W. Wang, S. R. Riddell, C. Yee, and T. Spies. 2005. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 102:6461-6466.
50. Dhodapkar, K. M., J. Krasovsky, B. Williamson, and M. V. Dhodapkar. 2002. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133.
51. Liao, X., Y. Li, C. Bonini, S. Nair, E. Gilboa, P. D. Greenberg, and C. Yee. 2004. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9:757-764.
52. Boczkowski, D., S. K. Nair, J. H. Nam, H. K. Lyerly, and E. Gilboa, editors. 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. 1028-1034 pp.
53. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. Journal of Experimental Medicine 184:465-472.
54. Zaremba, S., E. Barzaga, M. Zhu, N. Soares, K. Y. Tsang, and J. Schlom. 1997. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Research 57:4570-4577.
55. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A∗0201-binding residues. Journal of Immunology 157:2539-2548.
56. Jackson, M. R., E. S. Song, Y. Yang, and P. A. Peterson. 1992. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci U S A 89:12117-12121.
57. Cai, Z., A. Brunmark, M. R. Jackson, D. Loh, P. A. Peterson, and J. Sprent. 1996. Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc Natl Acad Sci U S A 93:14736-14741.
58. Latouche, J. B., and M. Sadelain. 2000. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 18:405-409.
59. Dupont, J., J. B. Latouche, C. Ma, and M. Sadelain. 2005. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 65:5417-5427.
60. Maus, M. V., A. K. Thomas, D. G. Leonard, D. Allman, K. Addya, K. Schlienger, J. L. Riley, and C. H. June. 2002. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20:143-148.
61. Maus, M. V., J. L. Riley, W. W. Kwok, G. T. Nepom, and C. H. June. 2003. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol 106:16-22.
62. Oelke, M., M. V. Maus, D. Didiano, C. H. June, A. Mackensen, and J. P. Schneck. 2003. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9:619-624.
63. Hirano, N., M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansen, and L. M. Nadler. 2006. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 12:2967-2975.
64. Yee, C. 2005. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med 3:17.
65. Mitchell, M. S. 2002. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. Journal of Clinical Oncology 20:1075-1086.
66. Dudley, M. E. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Journal of Immunotherapy 24:363-373.
67. Dudley, M. E., J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. M. Sherry, F. M. Marincola, S. F. Leitman, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, A. Nahvi, S. A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. Journal of Immunotherapy 25:243-251.
68. Meidenbauer, N., J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen. 2003. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 170:2161-2169.
69. Mackensen, A., N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen. 2006. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060-5069.
70. Tsuji, T., M. Yasukawa, J. Matsuzaki, T. Ohkuri, K. Chamoto, D. Wakita, T. Azuma, H. Niiya, H. Miyoshi, K. Kuzushima, Y. Oka, H. Sugiyama, H. Ikeda, and T. Nishimura. 2005. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106:470-476.
71. Clay, T. M., M. C. Custer, P. J. Spiess, and M. I. Nishimura. 1999. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathol Oncol Res 5:3-15.
72. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J Immunol 163:507-513.
73. Morgan, R. A., M. E. Dudley, Y. Y. Yu, Z. Zheng, P. F. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171:3287-3295.
74. Gade, T. P., W. Hassen, E. Santos, G. Gunset, A. Saudemont, M. C. Gong, R. Brentjens, X. S. Zhong, M. Stephan, J. Stefanski, C. Lyddane, J. R. Osborne, I. M. Buchanan, S. J. Hall, W. D. Heston, I. Riviere, S. M. Larson, J. A. Koutcher, and M. Sadelain. 2005. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65:9080-9088.
75. Zhao, Y., Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan. 2005. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 174:4415-4423.
76. Willemsen, R. A., M. E. Weijtens, C. Ronteltap, Z. Eshhar, J. W. Gratama, P. Chames, and R. L. Bolhuis. 2000. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 7:1369-1377.
77. Calogero, A., G. A. Hospers, K. M. Kruse, P. I. Schrier, N. H. Mulder, E. Hooijberg, and L. F. de Leij. 2000. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res 20:1793-1799.
78. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2006. Facilitating matched pairing and expression of TCR-chains introduced into human T-cells. Blood
79. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, H. J. Stauss, and M. Theobald. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2:962-970.
80. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. C. Chen, J. C. Yang, S. A. Rosenberg, and P. Hwu. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106-6115.
81. Gyobu, H., T. Tsuji, Y. Suzuki, T. Ohkuri, K. Chamoto, M. Kuroki, H. Miyoshi, Y. Kawarada, H. Katoh, T. Takeshima, and T. Nishimura. 2004. Generation and targeting of human tumorspecific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 64:1490-1495.
82. Finney, H. M., A. D. Lawson, C. R. Bebbington, and A. N. Weir. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791-2797.
83. Kowolik, C. M., M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J. Cooper. 2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66:10995-11004.
84. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063-1074.
85. Greenberg, P. D., M. A. Cheever, and A. Fefer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes. Journal of Experimental Medicine 154:952-963.
86. Vierboom, M. P., G. M. Bos, M. Ooms, R. Offringa, and C. J. Melief. 2000. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 87:253-260.
87. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101:429-441.
88. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344.
89. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697.
90. Schiavoni, G., F. Mattei, T. Di Pucchio, S. M. Santini, L. Bracci, F. Belardelli, and E. Proietti. 2000. Cyclophosphamide induces type I interferon and augments the number of CD44 (hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024-2030.
91. Maguire, H. C., Jr., and V. L. Ettore. 1967. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48:39-43.
92. Lutsiak, M. E., R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom, and H. Sabzevari. 2005. Inhibition of CD4 (+) 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868.
93. Vierboom, M. P. M., H. W. Nijman, R. Offringa, E. I. H. Vandervoort, T. Vanhall, L. Vandenbroek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. M. Melief. 1997. Tumor Eradication By Wild-Type P53-Specific Cytotoxic T Lymphocytes. Journal of Experimental Medicine 186:695-704.
94. Berd, D., M. J. Mastrangelo, P. F. Engstrom, A. Paul, and H. Maguire. 1982. Augmentation of the human immune response by cyclophosphamide. Cancer Res 42:4862-4866.
95. Berd, D., and M. J. Mastrangelo. 1987. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47:3317-3321.
96. Bast, R. C., Jr., E. L. Reinherz, C. Maver, P. Lavin, and S. F. Schlossman. 1983. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28:101-114.
97. Berd, D., H. C. Maguire, Jr., and M. J. Mastrangelo. 1984. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 44:5439-5443.
98. Goldrath, A. W., P. V. Sivakumar, M. Glaccum, M. K. Kennedy, M. J. Bevan, C. Benoist, D. Mathis, and E. A. Butz. 2002. Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 195:1515-1522.
99. Brown, I. E., C. Blank, J. Kline, A. K. Kacha, and T. F. Gajewski. 2006. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 177:4521-4529.
100. Teague, R. M., B. D. Sather, J. A. Sacks, M. Z. Huang, M. L. Dossett, J. Morimoto, X. Tan, S. E. Sutton, M. P. Cooke, C. Ohlen, and P. D. Greenberg. 2006. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12:335-341.
101. Wang, L. X., R. Li, G. Yang, M. Lim, A. O'Hara, Y. Chu, B. A. Fox, N. P. Restifo, W. J. Urba, and H. M. Hu. 2005. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65:10569-10577.
102. Cesana, G. C., G. DeRaffele, S. Cohen, D. Moroziewicz, J. Mitcham, J. Stoutenburg, K. Cheung, C. Hesdorffer, S. Kim-Schulze, and H. L. Kaufman. 2006. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169-1177.
103. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, K. E. Morton, S. A. Mavroukakis, P. H. Duray, S. M. Steinberg, J. P. Allison, T. A. Davis, and S. A. Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377.
104. Hodi, F. S., M. C. Mihm, R. J. Soiffer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, R. Padera, M. T. Jaklitsch, S. Shankar, T. C. Chen, A. Korman, J. P. Allison, and G. Dranoff. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717.
105. Kortylewski, M., M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mule, W. G. Kerr, R. Jove, D. Pardoll, and H. Yu. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314-1321.